IN
Inhibrx Biosciences Inc.
INBX · NASDAQ
$109.35 +3.58% (+$3.78)
1M +5.52%
Market Cap $1.54B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$139.56
27.6% upside
Current Price
$109.35
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INBX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
-
N/A P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 48.36%
Rev. growth 15.98%
FCF growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROIC 99.35%
ROA 89.60%
Debt
43 /100
Moderate Int. coverage -7.88x
Current ratio 5.07x
Debt/Assets N/A
Stability
1 /100
Unstable EPS volatility 1,415.79%
Beta 3.67x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INBX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mark Lappe
Employees
110
Headquarters
La Jolla
Upcoming events
13 NOV
Earnings
Upcoming earnings report